GE HealthCare (GEHC) has inked an agreement with CardioNavix, which is part of the CDL Nuclear Technologies services group, to distribute GEHC's Flyrcado.
Flyrcado (F-18 flurpiridaz) injection is a cardiac imaging agent used with PET myocardial perfusion imaging (MPI). About 6 million MPI procedures are performed each year in the U.S., with about 5% to 10% of these being PET MPI exams, according to GEHC.
CDL offers end-to-end cardiac PET imaging resources to hospitals and outpatient practices throughout the U.S., GEHC said. The distribution agreement will begin in late 2025.
